Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Nurix Therapeutics Commences Public Offering Of $125M Of Its Common Stock And, In Lieu Of Common Stock, In Case Of Certain Investors, Pre-funded Warrants To Purchase Shares

Author: Benzinga Newsdesk | April 11, 2024 04:01pm

Nurix currently intends to use any net proceeds from this offering primarily to fund clinical development of its drug candidates, to fund research and development activities to expand its pipeline and for working capital and general corporate purposes.
 

Posted In: NRIX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist